150 related articles for article (PubMed ID: 2440994)
1. Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue.
Godridge H; Reynolds GP; Czudek C; Calcutt NA; Benton M
J Neurol Neurosurg Psychiatry; 1987 Jun; 50(6):775-8. PubMed ID: 2440994
[TBL] [Abstract][Full Text] [Related]
2. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome.
Yates CM; Simpson J; Gordon A; Maloney AF; Allison Y; Ritchie IM; Urquhart A
Brain Res; 1983 Nov; 280(1):119-26. PubMed ID: 6228286
[TBL] [Abstract][Full Text] [Related]
3. Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis.
Griffin WS; Sheng JG; McKenzie JE; Royston MC; Gentleman SM; Brumback RA; Cork LC; Del Bigio MR; Roberts GW; Mrak RE
Neurobiol Aging; 1998; 19(5):401-5. PubMed ID: 9880042
[TBL] [Abstract][Full Text] [Related]
4. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study.
Huang W; Alexander GE; Daly EM; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB
Am J Psychiatry; 1999 Dec; 156(12):1879-86. PubMed ID: 10588400
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease and Down's syndrome.
Price DL; Whitehouse PJ; Struble RG; Coyle JT; Clark AW; Delong MR; Cork LC; Hedreen JC
Ann N Y Acad Sci; 1982; 396():145-64. PubMed ID: 6217772
[No Abstract] [Full Text] [Related]
6. The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome.
Burger PC; Vogel FS
Am J Pathol; 1973 Nov; 73(2):457-76. PubMed ID: 4271339
[TBL] [Abstract][Full Text] [Related]
7. Down's syndrome and Alzheimer's dementia: defining an association.
Heston LL
Psychiatr Dev; 1984; 2(4):287-94. PubMed ID: 6241313
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous determination of DA, NA, 5HT and their metabolites in several rat brain areas by HPLC with electrochemical detection.
Achilli G; Perego C; Ponzio F; Algeri S
Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):67-72. PubMed ID: 6191373
[TBL] [Abstract][Full Text] [Related]
9. Monoamine metabolism in senile dementia of Alzheimer type.
Cross AJ; Crow TJ; Johnson JA; Joseph MH; Perry EK; Perry RH; Blessed G; Tomlinson BE
J Neurol Sci; 1983; 60(3):383-92. PubMed ID: 6195313
[TBL] [Abstract][Full Text] [Related]
10. Detection of Lewy bodies in Trisomy 21 (Down's syndrome).
Raghavan R; Khin-Nu C; Brown A; Irving D; Ince PG; Day K; Tyrer SP; Perry RH
Can J Neurol Sci; 1993 Feb; 20(1):48-51. PubMed ID: 8467429
[TBL] [Abstract][Full Text] [Related]
11. Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry.
Teipel SJ; Alexander GE; Schapiro MB; Möller HJ; Rapoport SI; Hampel H
Brain; 2004 Apr; 127(Pt 4):811-24. PubMed ID: 14985261
[TBL] [Abstract][Full Text] [Related]
12. Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia.
Pietrini P; Dani A; Furey ML; Alexander GE; Freo U; Grady CL; Mentis MJ; Mangot D; Simon EW; Horwitz B; Haxby JV; Schapiro MB
Am J Psychiatry; 1997 Aug; 154(8):1063-9. PubMed ID: 9247390
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin-releasing hormone, luteinizing hormone-releasing hormone and substance P immuno-reactivity in post-mortem brain from cases of Alzheimer-type dementia and Down's syndrome.
Yates CM; Harmar AJ; Rosie R; Sheward J; de Levy GS; Simpson J; Maloney AF; Gordon A; Fink G
Brain Res; 1983 Jan; 258(1):45-52. PubMed ID: 24010162
[TBL] [Abstract][Full Text] [Related]
14. Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease.
Vermeiren Y; Janssens J; Aerts T; Martin JJ; Sieben A; Van Dam D; De Deyn PP
J Alzheimers Dis; 2016 Jun; 53(3):1079-96. PubMed ID: 27314528
[TBL] [Abstract][Full Text] [Related]
15. Neurotransmitter dysfunction and atrophy of the caudate nucleus in Alzheimer's disease.
Pearce BR; Palmer AM; Bowen DM; Wilcock GK; Esiri MM; Davison AN
Neurochem Pathol; 1984-1985 Winter; 2(4):221-32. PubMed ID: 6085697
[TBL] [Abstract][Full Text] [Related]
16. Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease.
Hayn M; Kremser K; Singewald N; Cairns N; Nemethova M; Lubec B; Lubec G
Life Sci; 1996; 59(7):537-44. PubMed ID: 8761342
[TBL] [Abstract][Full Text] [Related]
17. An update on the neurochemistry of Alzheimer disease.
Davies P
Adv Neurol; 1983; 38():75-86. PubMed ID: 6137134
[No Abstract] [Full Text] [Related]
18. The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid.
Lalowski M; Golabek A; Lemere CA; Selkoe DJ; Wisniewski HM; Beavis RC; Frangione B; Wisniewski T
J Biol Chem; 1996 Dec; 271(52):33623-31. PubMed ID: 8969231
[TBL] [Abstract][Full Text] [Related]
19. Neurotransmitters in rats fed fumonisin B1.
Porter JK; Voss KA; Chamberlain WJ; Bacon CW; Norred WP
Proc Soc Exp Biol Med; 1993 Mar; 202(3):360-4. PubMed ID: 7679795
[TBL] [Abstract][Full Text] [Related]
20. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).
Gottfries CG; Adolfsson R; Aquilonius SM; Carlsson A; Eckernäs SA; Nordberg A; Oreland L; Svennerholm L; Wiberg A; Winblad B
Neurobiol Aging; 1983; 4(4):261-71. PubMed ID: 6200784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
